Statins Added to Chronic Hepatitis C Treatment: Is it Beneficial?Mohamed AA1, El-Halawany F2, El-Nabarawy N3, Zayed N4, Omar H4*, El-Kasas M5 and El-Gohary K6
- *Corresponding Author:
- Omar H
MD, Lecturer in Endemic Medicine and Hepatology
Department, Faculty of Medicine, Cairo University, Egypt
Email: [email protected]
Received date: February 12, 2016; Accepted date: February 24, 2016; Published date: March 02, 2016
Citation: Mohamed AA, El-Halawany F, El-Nabarawy N, Zayed N, Omar H, et al. (2016) Statins Added to Chronic Hepatitis C Treatment: Is it Beneficial?. J Hepatol Gastroint Dis 2:117. doi:10.4172/2475-3181.1000117
Copyright: © 2016 Mohamed AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Chronic hepatitis C (CHC) is a major health problem in Egypt with about 9.8% of Egyptian population having an active hepatitis C infection. Almost Every step in the Hepatitis C virus (HCV) life cycle is closely related to lipid metabolism. HCV circulate in the body in lipid-rich particle, attach to hepatocytes via lipoprotein receptors. Recent attention focused on HMG CoA Reductase inhibitors (statins) and their potential therapeutic role in hepatitis C.
Methods: This retrospective closed cohort study included 60 naïve CHC patients. The HCV statins group patients (n = 26) received the combination of Standard of care (Interferon alfa and repavirin) and fluvastatin 80 mg daily; HCV non statins group (n = 43) treated with the SOC treatment only. Both groups receive their treatment over a duration of 48 weeks.
Results: On-treatment viral responses as well as the SVR were significantly better in HCV statins group in comparison to HCV non statins group; rapid virological response (RVR), early virological response (EVR) and sustained virological response (SVR) were (13.3%, 73.3% and 68.3%) in HCV statins group vs. (0%, 58.8% and 52.9%) HCV non statins group with p value 0.00, 0.003 and 0.003 respectively. Multivariate logistic regression model identified statins use as a significant predictor of an SVR.
Conclusion: A combination of fluvastatin and SOC significantly improved the SVR in naïve CHC Egyptian patients. Further powered randomized control trails are needed to elucidate statins role in HCV treatment.